Patents by Inventor Tarek Mohamed Ahmed Abdel-Fatah

Tarek Mohamed Ahmed Abdel-Fatah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biomarker SPAG5
    Patent number: 10775381
    Abstract: There has been a recent shift in cancer therapy from one size fits all to a personalized and tailored treatment for individual patients to increase efficiency and avoid unnecessary toxicity. This invention relates to a method of determining the prognosis and suitable treatment of cancer in a subject by measuring the level of expression of SPAG5. In particular, it relates to a method where high expression of SPAG5 in tumour cells correlates with aggressive tumours.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: September 15, 2020
    Assignees: NOTTINGHAM TRENT UNIVERSITY, NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST
    Inventors: Graham Roy Ball, Stephen Yan Tat Chan, Tarek Mohamed Ahmed Abdel-Fatah
  • Biomarker SPAG5
    Publication number: 20170138947
    Abstract: There has been a recent shift in cancer therapy from one size fits all to a personalized and tailored treatment for individual patients to increase efficiency and avoid unnecessary toxicity. This invention relates to a method of determining the prognosis and suitable treatment of cancer in a subject by measuring the level of expression of SPAG5. In particular, it relates to a method where high expression of SPAG5 in tumour cells correlates with aggressive tumors.
    Type: Application
    Filed: January 27, 2017
    Publication date: May 18, 2017
    Inventors: Graham Roy Ball, Stephan Yan Tat Chan, Tarek Mohamed Ahmed Abdel-Fatah
  • Biomarker SPAG5
    Publication number: 20150185219
    Abstract: There has been a recent shift in cancer therapy from one size fits all to a personalized and tailored treatment for individual patients to increase efficiency and avoid unnecessary toxicity. This invention relates to a method of determining the prognosis and suitable treatment of cancer in a subject by measuring the level of expression of SPAG5. In particular, it relates to a method where high expression of SPAG5 in tumour cells correlates with aggressive tumours.
    Type: Application
    Filed: May 31, 2013
    Publication date: July 2, 2015
    Applicants: Nottingham University Hospitals NHS Trust, Nottingham Trent University
    Inventors: Graham Roy Ball, Stephan Yan Tat Chan, Tarek Mohamed Ahmed Abdel-Fatah